54 centers across 6 countries administered Cabazitaxel 25 mg/m2 every 3 weeks was administered with prednisone 10mg daily. The primary endpoint was real-world use. Secondary endpoints included response rates, progression-free survival, overall survival, safety and health-related quality of life. 189 patients were included in the analysis. Median age was 69 years with 94% having an ECOG <1. Median Charleston comorbidity index was 4.0. The median number of cycles administered was 6 with 56% of patients utilizing G-CSF throughout therapy.
Health-related quality of life improvement during cabazitaxel treatment was recorded in one-third of patients and deterioration in 27% of patients. The greatest improvements were seen in the prostate-specific concerns and patient control subscales. The largest decline was for the functional and physical well-being subsets.
To the authors' knowledge, this is the first report of pain improvement on Cabazitaxel for patients with mCRPC. Real world data give physicians a better understanding of the effectiveness of cabazitaxel and its impact on mCRPC quality of life.
Presented by: Angelika Pichler, MD Leoben, Austria
Co-Authors: Joan Carles, MD, PhD, Vall d’Hebron University Hospital, Oncology Department, Barcelona , Gisoo Barnes, Cambridge, MA, Jana Katolicka, Brno, Czech Republic, Hana Korunkova, Plzen, Czech Republic, Antoaneta Tomova, Plovdiv, Bulgaria, Marwan Ghosn, Fadi El Karak, Beirut, Lebanon, Irina Koroleva, Samara, Russian Federation, Joseph Makdessi, Beirut, Lebanon, Ayse Ozatilgan, Cambridge, MA, Simon Hitier, Chilly-Mazarin, France, Joan Carles*, Barcelona, Spain
Written by: David B. Cahn, DO, MBS Fox Chase Cancer Center Philadelphia, PA @dbcahn at the 2018 AUA Annual Meeting - May 18 - 21, 2018 – San Francisco, CA USA
Read More on CAPRISTANA from the 2018 AUA: The Effectiveness and Safety of Cabazitaxel in Patients with mCRPC in Routine Clinical Practice: Results of CAPRISTANA